Detalhe da pesquisa
1.
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma.
Hematol Transfus Cell Ther
; 43(4): 417-423, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967807
2.
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience.
Rev Bras Hematol Hemoter
; 39(3): 216-222, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28830600
3.
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
Hematol., Transfus. Cell Ther. (Impr.)
; 43(4): 417-423, Oct.-Dec. 2021. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-1350799
4.
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
Rev. bras. hematol. hemoter
; 39(3): 216-222, July-Sept. 2017. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-898924
5.
Incidência de síndrome de lise tumoral aguda em pacientes portadores de hemopatias malignas / Incidence of acute tumor lysis syndrome in patients with malignant blood diseases
Bol. Soc. Bras. Hematol. Hemoter
; 16(167): 267-70, set.-dez. 1994. tab, graf
Artigo
em Português
| LILACS | ID: lil-201495